229 related articles for article (PubMed ID: 29719619)
1. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.
Nakayama K; Szewczyk MM; Dela Sena C; Wu H; Dong A; Zeng H; Li F; de Freitas RF; Eram MS; Schapira M; Baba Y; Kunitomo M; Cary DR; Tawada M; Ohashi A; Imaeda Y; Saikatendu KS; Grimshaw CE; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; Kiba A; Tomita D; Brown PJ
Oncotarget; 2018 Apr; 9(26):18480-18493. PubMed ID: 29719619
[TBL] [Abstract][Full Text] [Related]
2. Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
Milite C; Sarno G; Pacilio I; Cianciulli A; Viviano M; Iannelli G; Gazzillo E; Feoli A; Cipriano A; Chini MG; Castellano S; Bifulco G; Sbardella G
ChemMedChem; 2024 May; ():e202400139. PubMed ID: 38752332
[TBL] [Abstract][Full Text] [Related]
3. PRMT4 inhibitor TP-064 inhibits the pro-inflammatory macrophage lipopolysaccharide response in vitro and ex vivo and induces peritonitis-associated neutrophilia in vivo.
Zhang Y; de Boer M; van der Wel EJ; Van Eck M; Hoekstra M
Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166212. PubMed ID: 34311083
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent and dual-selective bisubstrate inhibitor for protein arginine methyltransferase 4/5.
Al-Hamashi AA; Chen D; Deng Y; Dong G; Huang R
Acta Pharm Sin B; 2021 Sep; 11(9):2709-2718. PubMed ID: 34589391
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
Shen Y; Szewczyk MM; Eram MS; Smil D; Kaniskan HÜ; de Freitas RF; Senisterra G; Li F; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J
J Med Chem; 2016 Oct; 59(19):9124-9139. PubMed ID: 27584694
[TBL] [Abstract][Full Text] [Related]
6. Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer.
Inoue F; Sone K; Toyohara Y; Tanimoto S; Takahashi Y; Kusakabe M; Kukita A; Honjoh H; Nishijima A; Taguchi A; Miyamoto Y; Tanikawa M; Iriyama T; Uchino MM; Tsuruga T; Wada-Hiraike O; Oda K; Osuga Y
Biochem Biophys Res Commun; 2022 Apr; 601():123-128. PubMed ID: 35245741
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.
Ferreira de Freitas R; Eram MS; Smil D; Szewczyk MM; Kennedy S; Brown PJ; Santhakumar V; Barsyte-Lovejoy D; Arrowsmith CH; Vedadi M; Schapira M
J Med Chem; 2016 Jul; 59(14):6838-47. PubMed ID: 27390919
[TBL] [Abstract][Full Text] [Related]
8. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
9. PRMT4 inhibitor TP-064 impacts both inflammatory and metabolic processes without changing the susceptibility for early atherosclerotic lesions in male apolipoprotein E knockout mice.
Zhang Y; Verwilligen RAF; de Boer M; Sijsenaar TJP; Van Eck M; Hoekstra M
Atherosclerosis; 2021 Dec; 338():23-29. PubMed ID: 34785428
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia.
Guo Z; Zhang Z; Yang H; Cao D; Xu X; Zheng X; Chen D; Wang Q; Li Y; Li J; Du Z; Wang X; Chen L; Ding J; Shen J; Geng M; Huang X; Xiong B
J Med Chem; 2019 Jun; 62(11):5414-5433. PubMed ID: 31117515
[TBL] [Abstract][Full Text] [Related]
11. Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1.
Ran T; Li W; Peng B; Xie B; Lu T; Lu S; Liu W
J Chem Inf Model; 2019 Jan; 59(1):522-534. PubMed ID: 30607947
[TBL] [Abstract][Full Text] [Related]
12. Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.
Sutherland M; Li A; Kaghad A; Panagopoulos D; Li F; Szewczyk M; Smil D; Scholten C; Bouché L; Stellfeld T; Arrowsmith CH; Barsyte D; Vedadi M; Hartung IV; Steuber H; Britton R; Santhakumar V
ChemMedChem; 2021 Apr; 16(7):1116-1125. PubMed ID: 33513288
[TBL] [Abstract][Full Text] [Related]
13. Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.
Bhattacharya D; Shi Ming Li A; Paul B; Ghosh Dastidar U; Santhakumar V; Sarkar D; Chau I; Li F; Ghosh T; Vedadi M; Talukdar A
Eur J Med Chem; 2023 Nov; 260():115713. PubMed ID: 37597437
[TBL] [Abstract][Full Text] [Related]
14. Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis.
Lai Y; Li X; Li T; Li X; Nyunoya T; Chen K; Kitsios G; Nouraie M; Zhang Y; McVerry BJ; Lee JS; Mallmapalli RK; Zou C
Thorax; 2023 Apr; 78(4):383-393. PubMed ID: 35354645
[TBL] [Abstract][Full Text] [Related]
15. Endotoxin stabilizes protein arginine methyltransferase 4 (PRMT4) protein triggering death of lung epithelia.
Lai Y; Li X; Li T; Nyunoya T; Chen K; Kitsios GD; Nouraie SM; Zhang Y; McVerry BJ; Lee JS; Mallampalli RK; Zou C
Cell Death Dis; 2021 Sep; 12(9):828. PubMed ID: 34480022
[TBL] [Abstract][Full Text] [Related]
16. Identification and
Berberich H; Terwesten F; Rakow S; Sahu P; Bouchard C; Meixner M; Philipsen S; Kolb P; Bauer UM
FEBS Open Bio; 2017 Dec; 7(12):1909-1923. PubMed ID: 29226078
[TBL] [Abstract][Full Text] [Related]
17. CARM1/PRMT4 is necessary for the glycogen gene expression programme in skeletal muscle cells.
Wang SC; Dowhan DH; Eriksson NA; Muscat GE
Biochem J; 2012 Jun; 444(2):323-31. PubMed ID: 22428544
[TBL] [Abstract][Full Text] [Related]
18. Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4).
Gunnell EA; Al-Noori A; Muhsen U; Davies CC; Dowden J; Dreveny I
Biochem J; 2020 Feb; 477(4):787-800. PubMed ID: 32011657
[TBL] [Abstract][Full Text] [Related]
19. Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders.
Xie H; Bacabac MS; Ma M; Kim EJ; Wang Y; Wu W; Li L; Xu W; Tang W
J Med Chem; 2023 Sep; 66(18):13028-13042. PubMed ID: 37703322
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of selective, small molecule inhibitors of coactivator-associated arginine methyltransferase 1 (CARM1).
Kaniskan HÜ; Eram MS; Liu J; Smil D; Martini ML; Shen Y; Santhakumar V; Brown PJ; Arrowsmith C; Vedadi M; Jin J
Medchemcomm; 2016 Sep; 7(9):1793-1796. PubMed ID: 28042453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
